BioCentury
ARTICLE | Clinical News

Sanofi oral Fabry's therapy gets Fast Track

April 29, 2015 12:28 AM UTC

The Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) said FDA granted Fast Track designation for GZ402671 to treat Fabry's disease.

Last week, Sanofi began a Phase IIa trial of the glucosylceramide synthase (GCS) inhibitor. GZ402671 is an oral substrate reduction therapy; there are no marketed oral treatments for Fabry's disease. ...